Pancreatic cancer: Promise for personalised medicine?

Cancer Letters

Volumn 318, Issue 1, 2012, Pages 1-8

  Braat, Henri ^a   Bruno, Marco ^a   Kuipers, Ernst J ^a   Peppelenbosch, Maikel P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biologicals; Diagnosis; Pancreas; Pathogenesis; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; METFORMIN; PLACEBO; SONIC HEDGEHOG PROTEIN; TEMSIROLIMUS;

CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CELL INTERACTION; CHRONIC INFLAMMATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DNA METHYLATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; MUCINOUS CARCINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREATIC STELLATE CELL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

EID: 84857138357     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.034     Document Type: Review

References (54)

1. Sener S.F., Fremgen A., Menck H.R., Winchester D.P. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J. Am. College Surg. 1999, 189:1-7.
2. Riediger H., Keck T., Wellner U., zur Hausen A., Adam U., Hopt U.T., Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J. Gastrointest. Surg. 2009, 13:1337-1344.
3. Rustgi A.K. The molecular pathogenesis of pancreatic cancer: clarifying a complex circuitry. Genes Dev. 2006, 20:3049-3053.
4. de Jong K., Nio C.Y., Hermans J.J., Dijkgraaf M.G., Gouma D.J., van Eijck C.H., van Heel E., Klass G., Fockens P., Bruno M.J. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin. Gastroenterol. Hepatol. 2010, 8:806-811.
5. Yamaguchi K., Kanemitsu S., Hatori T., Maguchi H., Shimizu Y., Tada M., Nakagohri T., Hanada K., Osanai M., Noda Y., Nakaizumi A., Furukawa T., Ban S., Nobukawa B., Kato Y., Tanaka M. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 2011, 40:571-580.
6. Takasu N., Kimura W., Moriya T., Hirai I., Takeshita A., Kamio Y., Nomura T. Intraductal papillary-mucinous neoplasms of the gastric and intestinal types may have less malignant potential than the pancreatobiliary type. Pancreas 2010, 39:604-610.
7. Grapin-Botton A. Ductal cells of the pancreas. Int. J. Biochem. Cell Biol. 2005, 37:504-510.
8. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., Kamiyama M., Hruban R.H., Eshleman J.R., Nowak M.A., Velculescu V.E., Kinzler K.W., Vogelstein B., Iacobuzio-Donahue C.A. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
9. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
10. Malumbres M., Barbacid M. RAS oncogenes: the first 30years. Nat. Rev. Cancer 2003, 3:459-465.
11. Shi C., Hong S.-M., Lim P., Kamiyama H., Khan M., Anders R.A., Goggins M., Hruban R.H., Eshleman J.R. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with panin: implications for the human pancreatic cancer cell of origin. Mol. Cancer Res. 2009, 7:230-236.
12. Satoh K., Shimosegawa T., Moriizumi S., Koizumi M., Toyota T. K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas 1996, 12:362-368.
13. Kitago M., Ueda M., Aiura K., Suzuki K., Hoshimoto S., Takahashi S., Mukai M., Kitajima M. Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. Int. J. Cancer 2004, 110:177-182.
14. Buchholz M., Braun M., Heidenblut A., Kestler H.A., Kloppel G., Schmiegel W., Hahn S.A., Luttges J., Gress T.M. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 2005, 24:6626-6636.
15. Wilentz R.E., Iacobuzio-Donahue C.A., Argani P., McCarthy D.M., Parsons J.L., Yeo C.J., Kern S.E., Hruban R.H. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000, 60:2002-2006.
16. Wilentz R.E., Su G.H., Dai J.L., Sparks A.B., Argani P., Sohn T.A., Yeo C.J., Kern S.E., Hruban R.H. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am. J. Pathol. 2000, 156:37-43.
17. Nakata K., Nagai E., Ohuchida K., Aishima S., Hayashi A., Miyasaka Y., Yu J., Mizumoto K., Tanaka M., Tsuneyoshi M. REG4 is associated with carcinogenesis in the 'intestinal' pathway of intraductal papillary mucinous neoplasms. Mod. Pathol. 2009, 22:460-468.
18. Basturk O., Khayyata S., Klimstra D.S., Hruban R.H., Zamboni G., Coban I., Adsay N.V. Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am. J. Surg. Pathol. 2010, 34:364-370.
19. van Lier M.G., Westerman A.M., Wagner A., Looman C.W., Wilson J.H., de Rooij F.W., Lemmens V.E., Kuipers E.J., Mathus-Vliegen E.M., van Leerdam M.E. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 2011, 60:141-147.
20. Klumpen H.J., Queiroz K.C., Spek C.A., van Noesel C.J., Brink H.C., de Leng W.W., de Wilde R.F., Mathus-Vliegen E.M., Offerhaus G.J., Alleman M.A., Westermann A.M., Richel D.J. mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. J. Clin. Oncol. 2011, 29:e150-153.
21. Javle M.M., Shroff R.T., Xiong H., Varadhachary G.A., Fogelman D., Reddy S.A., Davis D., Zhang Y., Wolff R.A., Abbruzzese J.L. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010, 10:368.
22. Lee M.-S., Hsu C.-C., Wahlqvist M., Tsai H.-N., Chang Y.-H., Huang Y.-C. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011, 11:20.
23. M. MacKenzie, S. Ernst, C. Johnson, E. Winquist, A phase I study of temsirolimus and metformin in advanced solid tumours, Investigational New Drugs, 2010, pp. 1-6.
24. Kawahira H., Scheel D.W., Smith S.B., German M.S., Hebrok M. Hedgehog signaling regulates expansion of pancreatic epithelial cells. Dev. Biol. 2005, 280:111-121.
25. Bachem M.G., Schünemann M., Ramadani M., Siech M., Beger H., Buck A., Zhou S., Schmid-Kotsas A., Adler G. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005, 128:907-921.
26. Erkan M., Reiser-Erkan C., Michalski C.W., Deucker S., Sauliunaite D., Streit S., Esposito I., Friess H., Kleeff J. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 2009, 11:497-508.
27. Vonlaufen A., Joshi S., Qu C., Phillips P.A., Xu Z., Parker N.R., Toi C.S., Pirola R.C., Wilson J.S., Goldstein D., Apte M.V. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008, 68:2085-2093.
28. Xu Z., Vonlaufen A., Phillips P.A., Fiala-Beer E., Zhang X., Yang L., Biankin A.V., Goldstein D., Pirola R.C., Wilson J.S., Apte M.V. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 2010, 177:2585-2596.
29. Jones S., Zhang X., Parsons D.W., Lin J.C.-H., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.-M., Fu B., Lin M.-T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
30. Bailey J.M., Swanson B.J., Hamada T., Eggers J.P., Singh P.K., Caffery T., Ouellette M.M., Hollingsworth M.A. Sonic Hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 2008, 14:5995-6004.
31. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Castillo C.F.-d., Yajnik V., Antoniu B., McMahon M., Warshaw A.L., Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
32. Dai J., Ai K., Du Y., Chen G. Sonic Hedgehog expression correlates with distant metastasis in pancreatic adenocarcinoma. Pancreas 2011, 40:233-236.
33. Yauch R.L., Gould S.E., Scales S.J., Tang T., Tian H., Ahn C.P., Marshall D., Fu L., Januario T., Kallop D., Nannini-Pepe M., Kotkow K., Marsters J.C., Rubin L.L., de Sauvage F.J. A paracrine requirement for Hedgehog signalling in cancer. Nature 2008, 455:406-410.
34. Mueller M.T., Hermann P.C., Witthauer J., Rubio-Viqueira B., Leicht S.F., Huber S., Ellwart J.W., Mustafa M., Bartenstein P., D'Haese J.G., Schoenberg M.H., Berger F., Jauch K.W., Hidalgo M., Heeschen C. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009, 137:1102-1113.
35. Nolan-Stevaux O., Lau J., Truitt M.L., Chu G.C., Hebrok M., Fernández-Zapico M.E., Hanahan D. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009, 23:24-36.
36. Hahn H., Wicking C., Zaphiropoulos P.G., Gailani M.R., Shanley S., Chidambaram A., Vorechovsky I., Holmberg E., Unden A.B., Gillies S., Negus K., Smyth I., Pressman C., Leffell D.J., Gerrard B., Goldstein A.M., Dean M., Toftgard R., Chenevix-Trench G., Wainwright B., Bale A.E. Mutations of the human homolog of drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:841-851.
37. Xie J., Murone M., Luoh S.-M., Ryan A., Gu Q., Zhang C., Bonifas J.M., Lam C.-W., Hynes M., Goddard A., Rosenthal A., Jr E.H.E., de Sauvage F.J. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 1998, 391:90-92.
38. Von Hoff D.D., LoRusso P.M., Rudin C.M., Reddy J.C., Yauch R.L., Tibes R., Weiss G.J., Borad M.J., Hann C.L., Brahmer J.R., Mackey H.M., Lum B.L., Darbonne W.C., Marsters J.C., de Sauvage F.J., Low J.A. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. New England J. Med. 2009, 361:1164-1172.
39. Yauch R.L., Dijkgraaf G.J.P., Alicke B., Januario T., Ahn C.P., Holcomb T., Pujara K., Stinson J., Callahan C.A., Tang T., Bazan J.F., Kan Z., Seshagiri S., Hann C.L., Gould S.E., Low J.A., Rudin C.M., de Sauvage F.J. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326:572-574.
40. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
41. Tapia N., Schöler H.R. p53 connects tumorigenesis and reprogramming to pluripotency. J. Exp. Med. 2010, 207:2045-2048.
42. DiGiuseppe J.A., Hruban R.H., Goodman S.N., Polak M., van den Berg F.M., Allison D.C., Cameron J.L., Offerhaus G.J. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am. J. Clin. Pathol. 1994, 101:684-688.
43. Ruggeri B.A., Huang L., Berger D., Chang H., Klein-Szanto A.J., Goodrow T., Wood M., Obara T., Heath C.W., Lynch H. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer 1997, 79:700-716.
44. Scarpa A., Capelli P., Mukai K., Zamboni G., Oda T., Iacono C., Hirohashi S. Pancreatic adenocarcinomas frequently show Tp53 gene mutations. Am. J. Pathol. 1993, 142:1534-1543.
45. Ruijs M.W.G., Verhoef S., Rookus M.A., Pruntel R., van der Hout A.H., Hogervorst F.B.L., Kluijt I., Sijmons R.H., Aalfs C.M., Wagner A., Ausems M.G.E.M., Hoogerbrugge N., van Asperen C.J., Gomez Garcia E.B., Meijers-Heijboer H., ten Kate L.P., Menko F.H., van 't Veer L.J. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J. Med. Gene. 2010, 47:421-428.
46. Campani D., Boggi U., Cecchetti D., Esposito I., Ceccarelli F., D'Antonio L., De Negri F., Mosca F., Bevilacqua G., Fornaciari G. p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer. Pancreas 1999, 19:26-32.
47. Hasebe T., Okada N., Tamura N., Houjoh T., Akashi-Tanaka S., Tsuda H., Shibata T., Sasajima Y., Iwasaki M., Kinoshita T. p53 expression in tumor stromal fibroblasts is associated with the outcome of patients with invasive ductal carcinoma of the breast. Cancer Sci. 2009, 100:2101-2108.
48. Patocs A., Zhang L., Xu Y., Weber F., Caldes T., Mutter G.L., Platzer P., Eng C. Breast-Cancer Stromal Cells with TP53 Mutations and Nodal Metastases. New England J. Med. 2007, 357:2543-2551.
49. Hong S.M., Kelly D., Griffith M., Omura N., Li A., Li C.P., Hruban R.H., Goggins M. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod. Pathol. 2008, 21:1499-1507.
50. de Jong K., Poley J.W., van Hooft J.E., Visser M., Bruno M.J., Fockens P. Endoscopic ultrasound-guided fine-needle aspiration of pancreatic cystic lesions provides inadequate material for cytology and laboratory analysis: initial results from a prospective study. Endoscopy 2011, 43:585-590.
51. Hirono S., Tani M., Kawai M., Ina S., Nishioka R., Miyazawa M., Fujita Y., Uchiyama K., Yamaue H. Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors. Arch Surg. 2009, 144:345-349. (discussion 349-350).
52. Poley J.W., Kluijt I., Gouma D.J., Harinck F., Wagner A., Aalfs C., van Eijck C.H., Cats A., Kuipers E.J., Nio Y., Fockens P., Bruno M.J. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am. J. Gastroenterol. 2009, 104:2175-2181.
53. Vasen H.F.A., Wasser M., van Mil A., Tollenaar R.A., Konstantinovski M., Gruis N.A., Bergman W., Hes F.J., Hommes D.W., Offerhaus G.J.A., Morreau H., Bonsing B.A., de Vos tot Nederveen Cappel W.H. Magnetic Resonance Imaging Surveillance Detects Early-Stage Pancreatic Cancer in Carriers of a p16-Leiden Mutation. Gastroenterology 2011, 140:850-856.
54. Nakata K., Ohuchida K., Aishima S., Sadakari Y., Kayashima T., Miyasaka Y., Nagai E., Mizumoto K., Tanaka M., Tsuneyoshi M., Oda Y. Invasive carcinoma derived from intestinal-type intraductal papillary mucinous neoplasm is associated with minimal invasion, colloid carcinoma, and less invasive behavior, leading to a better prognosis. Pancreas 2011, 40:581-587.